Company XLIE SCIE OTC Markets

Equities

XLSCF

CH0461929603

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per Business

Ratings for XLIE SCIE

EPS Revisions

Annual profits - Rate of surprise

Sector Other Biotechnology & Medical Research

Delayed OTC Markets Other stock markets			5-day change	1st Jan Change
- ^USD	-.--%		-.--%	-.--%

04-23	Xlife Sciences Posts Higher FY23 Profit; Revenue Falls	MT
02-29	Xlife Sciences AG Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Xlife Sciences AG is a Switzerland-based biotechnology company. The Company focuses on investing in technologies in the life science industry. It supports researchers and entrepreneurs in positioning, structuring, developing and implementing their concepts. The Company offers its investors direct access to the further development of technologies at a very early stage. The Company cooperates with industrial partners and universities.

CHF in Million	2022	Weight	2023	Weight	Delta
Not Allocated 66.0 %	1	72.8 %	1	66.0 %	-12.81%
Biotechnologies Therapies 34.0 %	0	27.2 %	0	34.0 %	+20.11%

CHF in Million	2022	Weight	2023	Weight	Delta
Switzerland 100.0 %	1	100.0 %	1	100.0 %	-3.85%

Managers	Title	Age	Since
Oliver Baumann CEO	Chief Executive Officer	-	19-06-30
Carl von Halem DFI	Director of Finance/CFO	-	21-11-30
Alexander Zink CTO	Chief Tech/Sci/R&D Officer	-	-
Simone Bonito ADM	Chief Administrative Officer	-	-
Frank Ploger CTO	Chief Tech/Sci/R&D Officer	-	20-10-31
Christian Faber CMP	Compliance Officer	-	19-09-11
Beat Kläui AUD	Comptroller/Controller/Auditor	-	-

Members of the board	Title	Age	Since
Christian Faber CMP	Compliance Officer	-	19-09-11
Mark Müller BRD	Director/Board Member	-	18-10-24
Oliver Baumann CEO	Chief Executive Officer	-	19-06-30
David Deck CHM	Chairman	-	22-06-19
Désirée Dosch BRD	Director/Board Member	-	22-06-19
Norbert Windhab BRD	Director/Board Member	-	22-06-19

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	5,703,292	2,838,803 ( 49.77 %)	0	49.77 %

Name	Equities	%	Valuation
Vartex International LLC 23.10 %	1,317,641	23.10 %	66 M $
Gilbert Schoeni 20.48 %	1,167,895	20.48 %	58 M $
Akira Holding AG 6.465 %	368,700	6.465 %	18 M $
OFZL AG 0.1753 %	10,000	0.1753 %	499 611 $
CATAM Asset Management AG 0.1403 %	7,999	0.1403 %	399 639 $
Gutmann Finanz Strategien AG 0.0359 %	2,048	0.0359 %	102 320 $
DWS CH AG 0.0183 %	1,042	0.0183 %	52 060 $

Xlife Sciences AG

Talacker 35

8001, Zurich

+41 44 385 84 60

http://www.xlifesciences.ch

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

32 CHF

Average target price

68 CHF

Spread / Average Target

+112.50%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
MODERNA, INC.	+26.28%	48.09B
IQVIA HOLDINGS INC.	-3.99%	40.43B
LONZA GROUP AG	+46.79%	40.62B
CELLTRION, INC.	-6.20%	28.36B
ICON PUBLIC LIMITED COMPANY	+6.36%	24.89B
ALNYLAM PHARMACEUTICALS, INC.	-21.47%	19.01B
MEDPACE HOLDINGS, INC.	+27.58%	12.09B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-2.75%	11.8B
BIO-TECHNE CORPORATION	-2.02%	11.88B

Other Biotechnology & Medical Research